Swiss Academies of Arts and Sciences
A patent waiver is not a silver bullet in the pursuit of vaccine equity
Covid-19 vaccine equity requires measures with immediate effect on their manufacturing and distribution in the Global South as well as improved compulsory licensing mechanisms, rather than a patent waiver. The low Covid-19 vaccination level in low- and middle-income countries is unacceptable and risks prolonging the pandemic, but a patent waiver will not solve this situation in the short-term. Instead, measures should be taken to accelerate local manufacturing and distribution of vaccines in these countries, ramp up investment in vaccination campaigns, and facilitate the compulsory licensing of patents and transfer of know-how. These are the main arguments in a new statement by ALLEA (European Federation of Academies of Sciences and Humanities).
